Clinical trial
Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab
NCT07310095 is registered in ClinicalTrials.gov with Xian-Janssen Pharmaceutical Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab
- Lead sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- December 30, 2025
- Completion date
- November 15, 2027
- Enrollment
- 78 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.